| Code | CSB-RA023981MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to YH002, targeting TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily Member 4), also known as OX40 or CD134. TNFRSF4 is a co-stimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell activation, proliferation, and survival. Upon binding its ligand OX40L, TNFRSF4 enhances T cell-mediated immune responses and promotes the generation of memory T cells. This receptor is implicated in various immune-mediated conditions including autoimmune diseases, allergic responses, and has garnered significant interest in cancer immunotherapy due to its ability to enhance anti-tumor immunity.
YH002 is a humanized agonistic monoclonal antibody against OX40. It binds to the OX40 on the surface of T cells, transmitting a strong activation signal, thereby enhancing the proliferation, survival, function and migration of T cells (especially effector T cells) to the tumor site, and strengthening the anti-tumor immune response. It is currently in clinical Phase II and is being evaluated for its efficacy and safety when combined with the PD-1 inhibitor Tislelizumab in the treatment of advanced solid tumors. This biosimilar provides researchers with a valuable tool for investigating OX40-mediated immune regulation, studying T cell co-stimulation mechanisms, and exploring therapeutic strategies in oncology and immunology research. The antibody enables detailed examination of TNFRSF4's role in immune checkpoint modulation and T cell function across various experimental models.
There are currently no reviews for this product.